Related references
Note: Only part of the references are listed.Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Sarit Schwartz et al.
CANCER CELL (2015)
Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
John R. Somoza et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethy12-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and P13Kδ for the Treatment of PTEN-Deficient Cancers
Bernard Barlaam et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond
Manman Wei et al.
MEDICINAL RESEARCH REVIEWS (2015)
BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma
Berengere Gobin et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors
Lydia W. T. Cheung et al.
CANCER CELL (2014)
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
Kira Gritsman et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Discovery and Optimization of Pyrimidone Indoline Amide P13Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers
Victor Certal et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Christine Fritsch et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy
Baptiste Ronan et al.
NATURE CHEMICAL BIOLOGY (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effects of Novel Isoform-Selective Phosphoinositide 3-Kinase Inhibitors on Natural Killer Cell Function
Sung Su Yea et al.
PLOS ONE (2014)
Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia
Xiang Wang et al.
ONCOTARGET (2014)
DW09849, a Selective Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Prevents PI3K Signaling and Preferentially Inhibits Proliferation of Cells Containing the Oncogenic Mutation p110α (H1047R)
Jia-li Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth
Xiang Wang et al.
ACTA PHARMACOLOGICA SINICA (2013)
P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse
Sunil Iyengar et al.
BLOOD (2013)
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Esther Castellano et al.
CANCER CELL (2013)
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2013)
Effects of isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts ACTIONS ON CYTOSKELETAL ORGANIZATION, SURVIVAL, AND RESORPTION
Ryan P. P. Shugg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]midazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
Chudi O. Ndubaku et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion
Sze Ki Luk et al.
EUROPEAN JOURNAL OF CANCER (2012)
Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
Jing Ni et al.
CANCER DISCOVERY (2012)
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types
Stephen Jamieson et al.
BIOCHEMICAL JOURNAL (2011)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)
A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
Meghan L. Rudd et al.
CLINICAL CANCER RESEARCH (2011)
Cancer immunology-analysis of host and tumor factors for personalized medicine
Shuji Ogino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda et al.
BLOOD (2010)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
pp60c-Src Phosphorylates and Activates Vacuolar Protein Sorting 34 to Mediate Cellular Transformation
Dianne S. Hirsch et al.
CANCER RESEARCH (2010)
The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
Alex Berndt et al.
NATURE CHEMICAL BIOLOGY (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
The PI3K Isoforms p110α and p110δ Are Essential for Pre-B Cell Receptor Signaling and B Cell Development
Faruk Ramadani et al.
SCIENCE SIGNALING (2010)
Share Paper
